SEPTInvestingStart Free
Stocks/ALZN/SEC Filings/8-K Nov 17, 2026

ALZN 8-K: Fda rejection

Filed with the SEC on Nov 17, 2026 · accession 0001214659-26-014504

ALZN filed a 8-K (current report) with the SEC on Nov 17, 2026. The FDA declined to support Alzamend Neuro's proposed modification of its Phase II bipolar disorder trial eligibility criteria, stating the trials were not designed as adequate and well-controlled studies. The stock moved -4.2% by the first close after the filing.

Summary of the filing

The FDA declined to support Alzamend Neuro's proposed modification of its Phase II bipolar disorder trial eligibility criteria, stating the trials were not designed as adequate and well-controlled studies. The company paused the trial, and Massachusetts General Hospital subsequently terminated the related statement of work, though the company plans to request a Type B meeting to discuss moving directly to a Phase III trial.

For details, click here →How to read a 8-K →

Key details

Refund from MGH for unused funds previously paid for the BD Clinical Trial$25K
RegistrantAlzamend Neuro, Inc.
Clinical trial partner; terminated bd sowThe General Hospital Corporation d/b/a Massachusetts General Hospital
Regulator; provided negative feedbackU.S. Food and Drug Administration

How ALZN stock reacted

Close before

$1.18

Nov 16, 2026

First close after

-4.24%

$1.13

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ALZN, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ALZN?

Click here

Frequently asked questions

What did ALZN file with the SEC on Nov 17, 2026?

ALZN filed a 8-K (Fda rejection). The FDA declined to support Alzamend Neuro's proposed modification of its Phase II bipolar disorder trial eligibility criteria, stating the trials were not designed as adequate and well-controlled studies. The company paused the trial, and Massachusetts General Hospital subsequently terminated the related statement of work, though the company plans to request a Type B meeting to discuss moving directly to a Phase III trial.

What does a fda rejection mean for ALZN stock?

For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did ALZN stock react to this filing?

ALZN closed at $1.18 before the filing and $1.13 on Nov 17, 2026 (-4.24%).

Other ALZN SEC filings

  • 8-K · Material agreementNov 10, 2026
  • 8-K · Fda approvalSep 29, 2026

Get alerts when ALZN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
ALZN overviewALZN analysisALZN newsLatest SEC filings
Source: SEC EDGAR filing 0001214659-26-014504. The summary and key details are extracted by SEPT from the filing and may contain errors. Price reaction uses daily closing prices. Not financial advice.